Navigation Links
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Date:2/10/2009

cyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

"We are pleased to be working with Cell Therapeutics to ensure that those patients with non-Hodgkin's Lymphoma who do not respond to current available therapies have access to pixantrone through a named patient program," said Natalie Douglas, CEO, IDIS. "CTI's potentially life-saving medicine can offer these patients renewed hope for remission. We are deeply committed to work in partnership with pharmaceutical and biotechnology companies to give physicians and their patients access to new and innovative medicines through regulated and responsible channels."

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). In January, 2009 CTI announced preliminary results that show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS, CR/CRu and ORR were determined by an independent
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
2. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
6. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
7. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
8. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
11. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...
(Date:12/15/2009)... Dec. 15 Dynatronics Corporation ... a preferred vendor agreement to provide therapy equipment ... (PTP), a nationwide network of physical, occupational and ... working with Preferred Therapy Providers," said Larry K. ... at Dynatronics. "Their vast network of 1,100 clinics ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... of the competitive environment is unquestionably ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...
Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 1Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 2Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 3Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 4Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 5Dallas Physician Elected to Lead International Organ Transplant Society 55053 1Dallas Physician Elected to Lead International Organ Transplant Society 55053 2Dallas Physician Elected to Lead International Organ Transplant Society 55053 3Gene Linked to Inherited Kidney Disease Found 55049 1
... PARIS, June 30 Five years after the ... disease causing accelerated and,premature ageing, a team of ... University of Oviedo - and Nicolas Levy and ... treatment,for the disease, using mice. This treatment, combining ...
... LONDON and PHILADELPHIA, June 30 ,GlaxoSmithKline (NYSE: GSK ... the U.S. Food and Drug Administration (FDA) for approval,of ... has submitted its response to questions raised by the ... In addition, given,that final data from GSK,s Phase III ...
Other Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 2GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 3
(Date:12/15/2009)... WHITE PLAINS, N.Y., Dec. 15 Team ... (LLS) groundbreaking charity sports training program, ... billion to support blood cancer research and patient ... has been the pre-eminent charity endurance sports training ... a marathon, half marathon, triathlon, 100-mile century cycle ...
(Date:12/15/2009)... 15 The new compact LifeSpan TR200 folding ... www.LifeSpanFitness.com ), was highly praised by treadmill review ... 2010. The compact TR200 folding treadmill received awards for ... under $1000. ,, The compact LifeSpan TR200 treadmill ... workout spaces. "This category buster is a very compact ...
(Date:12/15/2009)... to reduce depression and fatigue in people struggling with ... stems from an individual,s sense of mastery over ... certain physical goals. , The study appears in ... our arguments on fatigue being a symptom of depression," ... health at the University of Illinois and lead author ...
(Date:12/15/2009)... decade, the United Nations Foundation has led the fight ... World Malaria Report 2009 that the global strategies for ending malaria ... Health for the United Nations Foundation , ... Washington, ... United Nations Foundation has led the fight against malaria, ...
(Date:12/15/2009)... that phthalates actually cause the condition, experts ... Common chemicals found in plastic toys and elsewhere ... in boys, preliminary research suggests. , The ... pediatricians, adds fuel to the debate over these ... by some scientists. The chemical industry claims the ...
Breaking Medicine News(10 mins):Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3
... to provide additional modality integrationsINDIANAPOLIS, March 9 ... pleased to announce the worldwide release of its ... Key features of this release include integrated ECG ... Hemodynamic system. Synapse ProSolv cardiovascular 4.0.1 will ...
... Improvement Plus to Provide Information on Medicare Advantage ... Farmers MarketCOLUMBIA, S.C., March 9 A series ... Medicare beneficiaries with chronic illness maintain a healthy ... Plans designed for their unique needs will be ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... the latest findings in laboratory, translational and clinical cancer ... therapeutic approaches, as well as strides being made in ... the best advantage of the meeting,s scientific abstracts and ... will be available online at www.aacr.org on Friday, March ...
... Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., March ... IDMI ) today announced that the European Commission ... (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, ... that typically affects children and young adults. The ...
... author reviews the consequencesROCHESTER, Minn., March 9 ... the treating physician recommends discharge, the consequences may ... the need for readmission, according to a review ... Proceedings. Additionally, the article examines the effect of ...
Other Medicine News:Health News:ProSolv Releases New Cardiovascular Software 2Health News:ProSolv Releases New Cardiovascular Software 3Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: